Funding for this research was provided by:
Simons Foundation Autism Research Initiative (SFARI 342873)
National Institute of Child Health and Human Development (R01HD087048)
NIH Office of the Director (P51OD011107)
Stanford University Department of Psychiatry and Behavioral Sciences
Received: 25 January 2021
Accepted: 29 April 2021
First Online: 8 July 2021
: All procedures were reviewed and approved by the Institutional Animal Care and Use Committees (IACUCs) at the University of California, Davis and Stanford University. These procedures complied with the Guide for the Care and Use of Laboratory Animals and National Institutes of Health policies on the care and use of animals. The CNPRC and University of California, Davis, are accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC International).
: Not applicable.
: The Board of Trustees of the Leland Stanford Junior University and the regents of the University of California, San Francisco (UCSF) have filed patent applications related to biological measures studied herein (Stanford University: PCT/US2019/019029 “Methods for diagnosing and for determining severity of an autism spectrum disorder”; UCSF: PCT/US2016/014623 “Methods of diagnosing and treating autism spectrum disorders”). These patents have not been granted or licensed, and no study author is receiving any financial compensation at this time. EHS serves on the advisory board for Retrophin Inc. All other authors declare that they have no competing interests.